DiscoveryProbe™ FDA-approved Drug Library: Mechanistic Scope and HTS Evidence

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) contains 2,320 clinically validated compounds, encompassing a broad array of mechanisms including enzyme inhibition, receptor modulation, and signal pathway regulation (ApexBio). All compounds are approved or listed by major regulatory agencies (FDA, EMA, HMA, CFDA, PMDA) or pharmacopeias, ensuring verifiable sourcing and bioactivity. The library is pre-formulated as 10 mM DMSO solutions, stable for up to 24 months at -80°C, and is compatible with both high-throughput and high-content screening formats (96-well, deep well, barcoded tubes). Peer-reviewed screens have demonstrated its utility for drug repositioning and identification of novel targets, including viral protease inhibition with biostable, cell-permeable compounds (Sigurdardóttir et al., 2024). Multiple studies confirm the library's capacity to detect hits overlooked by in vitro-only methods, making it a cornerstone resource for translational research in oncology, neurodegeneration, and infectious disease (Matrix-Protein).

Biological Rationale

Small-molecule libraries composed of FDA-approved drugs enable rapid screening for bioactivity with known safety profiles. Drug repurposing accelerates therapeutic discovery by leveraging compounds with established pharmacokinetics and toxicology (Sigurdardóttir et al., 2024). The DiscoveryProbe™ FDA-approved Drug Library (L1021) was curated to address the need for a comprehensive, regulatory-validated resource for high-throughput screening (HTS) and high-content screening (HCS) applications. The inclusion of drugs with diverse mechanisms—spanning enzyme inhibitors, receptor agonists/antagonists, ion channel modulators, and pathway regulators—enables interrogation of complex biological processes across disease models. This supports rigorous pharmacological target identification and fosters translational research in oncology, neurodegenerative disorders, and infectious diseases (Fam-Azide-6-Isomer).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The L1021 library comprises compounds with well-characterized mechanisms, including:

• Enzyme Inhibitors: e.g., bortezomib (proteasome inhibitor), doxorubicin (topoisomerase II inhibitor).
• Receptor Agonists/Antagonists: e.g., metformin (AMPK activator), propranolol (β-adrenergic antagonist).
• Ion Channel Modulators: e.g., amlodipine (calcium channel blocker).
• Signaling Pathway Regulators: e.g., atorvastatin (HMG-CoA reductase inhibitor, affects cholesterol and MAPK signaling).

Each compound's mechanism is substantiated by clinical approval and literature evidence, supporting reliable mapping to pharmacological targets. The diversity of included drugs facilitates systematic interrogation of cellular processes, enabling identification of both anticipated and novel drug-target interactions. Notably, the library includes compounds effective in both cell-free and cellular assays, supporting discovery of membrane-permeable, biostable inhibitors (Sigurdardóttir et al., 2024).

Evidence & Benchmarks

• The DiscoveryProbe™ FDA-approved Drug Library (L1021) contains 2,320 compounds, each approved by at least one major regulatory agency or listed in a recognized pharmacopeia (ApexBio).
• Peer-reviewed screens of ~2,500-compound libraries (including L1021) in yeast identified eight confirmed inhibitors of SARS-CoV-2 main protease (MPro), five of which were proteasome inhibitors, demonstrating the platform's utility for antiviral drug repositioning (DOI:10.1128/spectrum.01249-24).
• Three boron-containing proteasome inhibitors (bortezomib, delanzomib, ixazomib) were experimentally validated as MPro inhibitors, confirming activity previously only predicted in silico; this required a non-standard buffer (50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM DTT, 100 mM NaCl, 0.01% Tween-20, 0.1 mg/mL BSA) for in vitro enzymatic assays (DOI:10.1128/spectrum.01249-24).
• Cellular assay systems (e.g., yeast MazF/FlipGFP) effectively detect inhibitors that are cell-permeable and biostable, filtering out general cytotoxins and compounds with poor intracellular stability (DOI:10.1128/spectrum.01249-24).
• The L1021 kit provides pre-dissolved 10 mM solutions in DMSO, with stability for 12 months at -20°C and 24 months at -80°C, supporting reproducibility across screening campaigns (ApexBio).
• Validated applications include oncology, neurodegenerative disease, infectious disease, and pathway mapping, as reviewed in comparative studies (Matrix-Protein).

Applications, Limits & Misconceptions

DiscoveryProbe™ FDA-approved Drug Library is widely used for:

• Drug repositioning screening: Rapid identification of new indications for approved drugs (Fam-Azide-6-Isomer).
• Pharmacological target identification: Mapping drug-target interactions in disease-relevant models.
• Cancer research drug screening: Systematic evaluation of compounds in oncology cell lines and xenografts.
• Neurodegenerative disease drug discovery: Identification of neuroprotective or disease-modifying agents.
• Signal pathway regulation and enzyme inhibitor screening: Dissecting cellular signaling mechanisms and enzymatic pathways.

This article extends previous analyses (Sulfo-Cy7 NHS Ester) by providing detailed evidence from recent peer-reviewed screens and practical workflow recommendations for high-content and high-throughput platforms.

Common Pitfalls or Misconceptions

• Not all compounds are equally active across species or disease models; pharmacodynamic differences must be empirically validated.
• Hits from in vitro enzymatic assays may not be cell-permeable or biostable in cellular systems (Sigurdardóttir et al., 2024).
• Some drug activities are buffer- and condition-dependent; for example, boron-containing proteasome inhibitors require specific buffer compositions to show antiviral activity (Sigurdardóttir et al., 2024).
• The library does not include investigational or experimental drugs lacking regulatory approval.
• General cytotoxicity may mask specific target effects in negative selection assays.

Workflow Integration & Parameters

The L1021 library is supplied as 10 mM solutions in DMSO, compatible with 96-well, deep well, and 2D barcoded storage formats. Shipping is on blue ice for evaluation samples, and at room temperature or on blue ice upon request for other sizes. Recommended storage is at -20°C (stable for 12 months) or -80°C (stable for 24 months). Typical screening dilutions range from 1–50 μM final concentration, depending on assay sensitivity. The library supports both high-throughput and high-content screening, enabling automated robotic integration. For enzymatic assays with boron-containing compounds, use 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 1 mM DTT, 100 mM NaCl, 0.01% Tween-20, and 0.1 mg/mL BSA to preserve activity (Sigurdardóttir et al., 2024).

Researchers should validate hit compounds in orthogonal assays and consider secondary profiling against off-targets and toxicity panels. For extended workflow guidance and comparative best practices, see DiscoveryProbe FDA-approved Drug Library: Applied Workflows, which this article updates with specific buffer and stability protocols for viral target screening.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) provides a rigorously validated, mechanistically diverse platform for high-throughput and high-content drug screening. Its inclusion of only regulatory-approved bioactives ensures relevance to translational research and clinical repositioning. Peer-reviewed evidence demonstrates the library's ability to identify cell-permeable, biostable inhibitors—such as boron-containing proteasome inhibitors against SARS-CoV-2 MPro—that may be missed by standard in vitro screens. Comprehensive mechanistic coverage, robust stability, and compatibility with modern HTS/HCS systems make this resource a leading standard for pharmacological target identification and drug repurposing. Ongoing updates in workflow integration and benchmarking will further enhance its utility in biomedical discovery.

For detailed compound lists and ordering information, see the DiscoveryProbe™ FDA-approved Drug Library product page.